Egotumab, a human antibody against colorectal cancer, to be presented Wednesday 31.10.2018 at 9:30 am in Basel, Switzerland.
Meet us at the conference.
BaseLaunch selected Cureab for phase I of its accelerator program in
We highly appreciate their trust in us.
About the program:
Baselaunch provides non-dilutive funding, no strings attached access to its
Healthcare Partners and knowledge from highly experienced advisors. Furthermore, Baselaunch embeds selected ventures deeply within the Basel region, one of
Europe’s finest biotech ecosystem.